How does ABBV's PE Ratio compare to its peers?

ABBV is expensive based on its Price-To-Earnings Ratio (63x) compared to the peer average (22.4x).

How does ABBV's PE Ratio compare vs other companies in the US Biotechs Industry?

ABBV is expensive based on its Price-To-Earnings Ratio (63x) compared to the US Biotechs industry average (16.4x).

What is ABBV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABBV is expensive based on its Price-To-Earnings Ratio (63x) compared to the estimated Fair Price-To-Earnings Ratio (48.2x).

What is the Fair Price of ABBV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ABBV ($181.14) is trading below our estimate of [[fair value]] ($467.95)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

AbbVie (NYSE:ABBV) - Stock Price, News & Analysis

ABBV Stock Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. More details

ABBV fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 61.3% below our estimate of its fair value

Earnings are forecast to grow 28.07% per year

Risk Analysis

Has a high level of debt

Large one-off items impacting financial results

Dividend of 3.62% is not well covered by earnings

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Cutting-Edge Neuroscience And Immunology Innovations Propel Future Growth And Expansion

Key Takeaways The integration of Cerevel Therapeutics and advancements in neuroscience and oncology are set to boost AbbVie's long-term revenue and margins. Growth in immunology and aesthetic segments, with products like SKYRIZI and BoNT/E, will support revenue increase and market penetration.

View narrative

US$204.74

11.5% undervalued

6.06%

Revenue growth p.a.

6 days ago

AbbVie Inc. Competitors

Amgen

NasdaqGS:AMGN

US$158.0b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$80.6b

Biogen

NasdaqGS:BIIB

US$23.1b

Horizon Therapeutics

NasdaqGS:HZNP

US$26.6b

Price History & Performance

Summary of all time highs, changes and price drops for AbbVie
Historical stock prices
Current Share Price	US$181.14
52 Week High	US$207.32
52 Week Low	US$137.65
Beta	0.61
11 Month Change	-3.57%
3 Month Change	-7.30%
1 Year Change	31.18%
33 Year Change	57.13%
5 Year Change	110.75%
Change since IPO	417.54%

Recent updates

AbbVie: Upgrading To 'Strong Buy' After Pullback

Nov 22

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

Nov 19

AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear

Nov 12

AbbVie Stock: Keep Calm And Buy The Dip

Nov 11

AbbVie: 3 Positives From The Earnings Report

Oct 30

AbbVie: Strong Dividends But Humira Disappoints

Oct 22

AbbVie: Dividend Discount Model Suggests Large Valuation Risks

Sep 29

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

Sep 06

Why AbbVie Remains One Of My Favorite Dividend Growers

Aug 27

AbbVie: Growth Is Still A Better Choice

Jul 29

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

Jul 17

AbbVie: A Hold Again (Rating Downgrade)

Jul 03

Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)

Jun 28

AbbVie: 5 Reasons That Make A Buy Case

Jun 18

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

May 29

Shareholder Returns

	ABBV	US Biotechs	US Market
7D	8.7%	4.0%	2.2%
1Y	31.2%	18.3%	32.6%

Return vs Industry: ABBV exceeded the US Biotechs industry which returned 18.3% over the past year.

Return vs Market: ABBV underperformed the US Market which returned 32.6% over the past year.

Price Volatility

Is ABBV's price volatile compared to industry and market?
ABBV volatility
ABBV Average Weekly Movement	4.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ABBV has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ABBV's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2012	50,000	Robert Michael	www.abbvie.com

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.

AbbVie Inc. Fundamentals Summary

How do AbbVie's earnings and revenue compare to its market cap?
ABBV fundamental statistics
Market cap	US$312.89b
Earnings (TTM)	US$5.08b
Revenue (TTM)	US$55.53b

63.0x

P/E Ratio

5.8x

P/S Ratio

Is ABBV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABBV income statement (TTM)
Revenue	US$55.53b
Cost of Revenue	US$16.47b
Gross Profit	US$39.06b
Other Expenses	US$33.98b
Earnings	US$5.08b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	2.88
Gross Margin	70.33%
Net Profit Margin	9.15%
Debt/Equity Ratio	1,174.8%

How did ABBV perform over the long term?

See historical performance and comparison

Dividends

3.6%

Current Dividend Yield

216%

Payout Ratio

Does ABBV pay a reliable dividends?

See ABBV dividend history and benchmarks

When do you need to buy ABBV by to receive an upcoming dividend?
AbbVie dividend dates
Ex Dividend Date	Jan 15 2025
Dividend Pay Date	Feb 14 2025
Days until Ex dividend	49 days
Days until Dividend pay date	79 days

Does ABBV pay a reliable dividends?

See ABBV dividend history and benchmarks

ABBV Stock Overview

Rewards

Risk Analysis

Cutting-Edge Neuroscience And Immunology Innovations Propel Future Growth And Expansion

AbbVie Inc. Competitors

NasdaqGS:AMGN

US$158.0b

NasdaqGS:REGN

US$80.6b

NasdaqGS:BIIB

US$23.1b

NasdaqGS:HZNP

US$26.6b

Price History & Performance

Recent News & Updates

AbbVie: Upgrading To 'Strong Buy' After Pullback

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter dividend of US$1.64 announced

Investor sentiment deteriorates as stock falls 15%

AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear

Recent updates

AbbVie: Upgrading To 'Strong Buy' After Pullback

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64

Abbvie Receives European Commission Approval of Elahere (Mirvetuximab Soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter dividend of US$1.64 announced

Investor sentiment deteriorates as stock falls 15%

AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia

AbbVie Stock: Keep Calm And Buy The Dip

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on February 14, 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie: 3 Positives From The Earnings Report

AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire Aliada Therapeutics, Inc. for $1.4 billion.

AbbVie: Strong Dividends But Humira Disappoints

U.S. FDA Approves AbbVie (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson's Disease

Upcoming dividend of US$1.55 per share

Allergan Aesthetics Announces Availability of Juvederm Voluma Xc for Moderate to Severe Temple Hollowing

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

AbbVie: Dividend Discount Model Suggests Large Valuation Risks

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Why AbbVie Remains One Of My Favorite Dividend Growers

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold US$12m worth of stock

Consensus EPS estimates fall by 10%

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

AbbVie: Growth Is Still A Better Choice

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Executive Chairman notifies of intention to sell stock

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie: A Hold Again (Rating Downgrade)

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) acquired Celsius Therapeutics, Inc. for $250 million.

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie: 5 Reasons That Make A Buy Case

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Shareholder Returns

Price Volatility

About the Company

AbbVie Inc. Fundamentals Summary